Previous close | 1.1500 |
Open | N/A |
Bid | 1.0500 |
Ask | 1.3500 |
Strike | 2.50 |
Expiry date | 2024-12-20 |
Day's range | 1.1500 - 1.1500 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Discover how icad Inc achieved a 14% revenue increase and improved operational metrics in the first quarter of 2024.
NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10%Total revenues were $5.0 million, up 14%Gross Profit Margin % was 83%, up from 82%GAAP Net Loss from
Call Time is 8:30 AM Eastern TimeNASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024. Earnings call details are as follows: Domestic: 877-545-0523International: 973-528-0016Participant Access Code: 730845Webcast: https: